We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Noble (NBL) Q2 Loss Narrower Than Expected, Revenues Miss
Read MoreHide Full Article
Noble Energy, Inc. reported second-quarter adjusted loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 39 cents. The company reported a loss of 10 cents per share in the year-ago quarter.
GAAP loss for the reported quarter was 85 cents compared with a loss of 2 cents per share in the year-ago period.
Total Revenues
Noble's total revenues were $571 million, lagging the Zacks Consensus Estimate of $642 million by 11%. Revenues also declined 47.8% from the year-ago quarter’s $1,093 million. This year-over-year decline was due to lower contribution from oil, NGL and gas sales, along with weak commodity prices.
Noble Energy Inc. Price, Consensus and EPS Surprise
In the quarter under review, sales volume averaged 350 thousand barrels of oil equivalent per day (MBoe/d), in line with the year-ago level. U.S. onshore volumes averaged 248 MBoe/d in the second quarter, down 5.7% from the prior-year period. The startup of Leviathan boosted volumes from the Eastern Mediterranean region.
Operating expenses for the reported quarter were $799 million, down 24.7% from the year-ago period. The decline was due to lower lease operating expenses, depreciation, depletion and amortization costs, as well as general and administrative expenses.
Interest expenses for the reported quarter were $87 million, up 38.1% from the year-ago period.
The company entered into a definite agreement to be acquired by Chevron Corporation. Chevron is set to acquire all outstanding shares of Noble in an all-stock transaction valued at $10.38 per share or nearly $5 billion.
Realized Prices
U.S. onshore realized crude oil and condensate prices (including derivatives) for the reported quarter decreased 44.5% to $32.28 per barrel from the year-ago level of $58.13.
U.S. onshore natural gas prices were $1.16 per thousand cubic feet, down 34.5% year over year.
U.S. onshore realized prices for natural gas liquids also declined 44.5% from the year-ago quarter to $8.07 per barrel.
Financial Highlights
Noble's cash and cash equivalents as of Jun 30, 2020 were $324 million compared with $484 million on Dec 31, 2019.
Long-term debt was $7,936 million as of Jun 30, 2020 compared with $7,477 million on Dec 31, 2019.
Cash flow from operating activities for first-half 2020 was $400 million, down from $1,092 million in first-half 2019.
Devon Energy Corporation (DVN - Free Report) is slated to report second-quarter 2020 earnings on Aug 4. The Zacks Consensus Estimate for the bottom line for the quarter is pegged at a loss of 26 cents.
Murphy Oil Corporation (MUR - Free Report) is slated to report second-quarter 2020 earnings on Aug 6. The Zacks Consensus Estimate for the to-be-reported quarter’s bottom line is pegged at a loss of $1.05.
Occidental Petroleum Corp. (OXY - Free Report) is slated to report second-quarter 2020 earnings on Aug 10. The Zacks Consensus Estimate for the bottom line is pegged at a loss of $1.66.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Noble (NBL) Q2 Loss Narrower Than Expected, Revenues Miss
Noble Energy, Inc. reported second-quarter adjusted loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 39 cents. The company reported a loss of 10 cents per share in the year-ago quarter.
GAAP loss for the reported quarter was 85 cents compared with a loss of 2 cents per share in the year-ago period.
Total Revenues
Noble's total revenues were $571 million, lagging the Zacks Consensus Estimate of $642 million by 11%. Revenues also declined 47.8% from the year-ago quarter’s $1,093 million. This year-over-year decline was due to lower contribution from oil, NGL and gas sales, along with weak commodity prices.
Noble Energy Inc. Price, Consensus and EPS Surprise
Noble Energy Inc. price-consensus-eps-surprise-chart | Noble Energy Inc. Quote
Highlights of the Release
In the quarter under review, sales volume averaged 350 thousand barrels of oil equivalent per day (MBoe/d), in line with the year-ago level. U.S. onshore volumes averaged 248 MBoe/d in the second quarter, down 5.7% from the prior-year period. The startup of Leviathan boosted volumes from the Eastern Mediterranean region.
Operating expenses for the reported quarter were $799 million, down 24.7% from the year-ago period. The decline was due to lower lease operating expenses, depreciation, depletion and amortization costs, as well as general and administrative expenses.
Interest expenses for the reported quarter were $87 million, up 38.1% from the year-ago period.
The company entered into a definite agreement to be acquired by Chevron Corporation. Chevron is set to acquire all outstanding shares of Noble in an all-stock transaction valued at $10.38 per share or nearly $5 billion.
Realized Prices
U.S. onshore realized crude oil and condensate prices (including derivatives) for the reported quarter decreased 44.5% to $32.28 per barrel from the year-ago level of $58.13.
U.S. onshore natural gas prices were $1.16 per thousand cubic feet, down 34.5% year over year.
U.S. onshore realized prices for natural gas liquids also declined 44.5% from the year-ago quarter to $8.07 per barrel.
Financial Highlights
Noble's cash and cash equivalents as of Jun 30, 2020 were $324 million compared with $484 million on Dec 31, 2019.
Long-term debt was $7,936 million as of Jun 30, 2020 compared with $7,477 million on Dec 31, 2019.
Cash flow from operating activities for first-half 2020 was $400 million, down from $1,092 million in first-half 2019.
Zacks Rank
Currently, Noble carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Upcoming Releases
Devon Energy Corporation (DVN - Free Report) is slated to report second-quarter 2020 earnings on Aug 4. The Zacks Consensus Estimate for the bottom line for the quarter is pegged at a loss of 26 cents.
Murphy Oil Corporation (MUR - Free Report) is slated to report second-quarter 2020 earnings on Aug 6. The Zacks Consensus Estimate for the to-be-reported quarter’s bottom line is pegged at a loss of $1.05.
Occidental Petroleum Corp. (OXY - Free Report) is slated to report second-quarter 2020 earnings on Aug 10. The Zacks Consensus Estimate for the bottom line is pegged at a loss of $1.66.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>